Evidence map›Paper›PMID 37973667›Full record

ArticleJournal of cardiovascular translational research2024

Upregulation of eIF2α by m

Jing Zhang, Wen-Qian Huang, Yu-Rong Zhang, Na Liang, Nan-Ping Li, Gang-Kai Tan, Shao-Xin Gong, Ai-Ping Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  3. Review
  4. METTL Family in Healthy and Disease.Molecular biomedicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing Zhang *Department of Physiology, Institute of Neuroscience Research, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Wen-Qian Huang *Department of Physiology, Institute of Neuroscience Research, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Yu-Rong ZhangDepartment of Physiology, Institute of Neuroscience Research, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Na LiangDepartment of Anesthesiology, Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421002, Hunan, People's Republic of China.
Nan-Ping LiDepartment of Physiology, Institute of Neuroscience Research, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Gang-Kai TanDepartment of Physiology, Institute of Neuroscience Research, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Shao-Xin GongDepartment of Pathology, First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China. 553648247@qq.com.
Ai-Ping WangDepartment of Physiology, Institute of Neuroscience Research, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China. waiping2011@163.com.ORCID 0000-0003-3392-0543

Funding

National Natural Science Foundation of China 81600040Natural Science Foundation of the Province of Hunan 2021JJ30601Research project of Health Commission of Hunan Province 202204114218Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province 21A0274
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a malignant cardiovascular disease. Eukaryotic initiation factor 2α (eIF2α) plays an important role in the proliferation of pulmonary artery smooth muscle cells (PASMCs) in hypoxia-induced pulmonary hypertension (HPH) rats. However, the regulatory mechanism of eIF2α remains poorly understood in PAH rats. Here, we discover eIF2α is markedly upregulated in monocrotaline (MCT)-induced PAH rats, eIF2α can be upregulated by mRNA methylation, and upregulated eIF2α can promote PASMC proliferation in MCT-PAH rats. GSK2606414, eIF2α inhibitor, can downregulate the expression of eIF2α and alleviate PASMC proliferation in MCT-PAH rats. And we further discover the mRNA of eIF2α has a common sequence with N 6-methyladenosine (m

Indexed as

Cell ProliferationDisease Models, AnimalEukaryotic Initiation Factor-2MonocrotalineMuscle, Smooth, VascularMyocytes, Smooth MusclePulmonary Arterial HypertensionPulmonary ArteryRats, Sprague-DawleyUp-RegulationAdenosineAnimalsCells, CulturedMaleMethylationMethyltransferasesAdenosineEukaryotic Initiation Factor-2MethyltransferasesMonocrotalineN-methyladenosineRNA, MessengereIF2αm6A methylationPASMCsPulmonary arterial hypertensionWTAP

Identifiers

PMID37973667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.